Trial Profile

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mycophenolate mofetil (Primary) ; Cyclophosphamide
Indications Interstitial lung diseases
Focus Therapeutic Use
Acronyms SLSII; The Scleroderma Lung Study II

Most Recent Events

08 Dec 2021 Results from Scleroderma Lung Studies (SLS) I and II evaluated the safety and efficacy of cyclophosphamide (SLS I and II) and mycophenolate (SLS II) for the treatment of SSc-ILD published in the Chest
30 Dec 2020 New trial record
12 Dec 2020 Results of a biomarker study using serum samples from this trial assessing predictive significance for longitudinal forced vital capacity percentage of six interferon inducible proteins (IP-10, MIG, MCP-2, B2M, TNFR2, and MIP-3 beta) published in the Arthritis and Rheumatology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com